Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

Autor: van de Loosdrecht AA; Department of Hematology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands. a.vandeloosdrecht@amsterdamumc.nl., Cremers EMP; Department of Hematology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands.; Department of Laboratory Medicine - Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., Alhan C; Department of Hematology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands., Duetz C; Department of Hematology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands., In 't Hout FEM; Department of Laboratory Medicine - Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., Visser-Wisselaar HA; HOVON Foundation, Rotterdam, The Netherlands., Chitu DA; HOVON Foundation, Rotterdam, The Netherlands.; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Verbrugge A; HOVON Foundation, Rotterdam, The Netherlands., Cunha SM; HOVON Foundation, Rotterdam, The Netherlands., Ossenkoppele GJ; Department of Hematology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands., Janssen JJWM; Department of Hematology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands., Klein SK; Department of Hematology, Meander Medisch Centrum, Amersfoort, The Netherlands.; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Vellenga E; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Huls GA; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Muus P; Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Haematology, St. James University Hospital, Leeds, UK., Langemeijer SMC; Department of Laboratory Medicine - Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., de Greef GE; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Te Boekhorst PAW; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Raaijmakers MHG; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van Marwijk Kooy M; Department of Hematology, Isala Ziekenhuis, Zwolle, The Netherlands., Legdeur MC; Department of Hematology, Medisch Spectrum Twente, Enschede, The Netherlands., Wegman JJ; Department of Hematology, Deventer Ziekenhuis, Deventer, The Netherlands.; Department of Hematology, Amsterdam UMC, location AMC, Amsterdam, The Netherlands., Deenik W; Department of Internal Medicine, Tergooi Ziekenhuis, Hilversum, The Netherlands.; Department of Internal Medicine, Rijnstate, Arnhem, the Netherlands., de Weerdt O; Department of Internal Medicine, St. Antonius Ziekenhuis, Nieuwegein, The Netherlands., van Maanen-Lamme TM; Department of Internal Medicine, Dijklander Ziekenhuis, Hoorn, The Netherlands., Jobse P; Department of Internal Medicine, Admiraal de Ruyter Ziekenhuis, Goes, The Netherlands., van Kampen RJW; Department of Internal Medicine, Zuyderland Ziekenhuis, Geleen, The Netherlands., Beeker A; Department of Hematology, Spaarne Gasthuis, Hoofddorp, The Netherlands., Wijermans PW; Department of Hematology, Haaglanden Ziekenhuis, Den Haag, The Netherlands., Biemond BJ; Department of Hematology, Amsterdam UMC, location AMC, Amsterdam, The Netherlands., Tanis BC; Department of Internal Medicine, Groene Hart Ziekenhuis, Gouda, The Netherlands.; Department of General Practice Erasmus MC, Rotterdam, The Netherlands., van Esser JWJ; Department of Internal Medicine, Amphia Ziekenhuis, Breda, The Netherlands., Schaar CG; Department of Internal Medicine, Gelre Ziekenhuis, Apeldoorn, The Netherlands., Noordzij-Nooteboom HS; Department of Internal Medicine, Van Weel Bethesda Ziekenhuis, Dirksland, The Netherlands., Jacobs EMG; Department of Internal Medicine, Elkerliek Ziekenhuis, Helmond, The Netherlands., de Graaf AO; Department of Laboratory Medicine - Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., Jongen-Lavrencic M; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Stevens-Kroef MJPL; Department of human genetics, Radboud University Medical Center, Nijmegen, The Netherlands., Westers TM; Department of Hematology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands., Jansen JH; Department of Laboratory Medicine - Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.

Publikováno v: Leukemia [Leukemia] 2024 Apr; Vol. 38 (4), pp. 840-850. Date of Electronic Publication: 2024 Jan 31.

Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?

Autor: Brooimans RA; Department of Immunology, Laboratory Medical Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands; Laboratory of Clinical and Tumor Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. Electronic address: r.brooimans@erasmusmc.nl., van der Velden VHJ; Department of Immunology, Laboratory Medical Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Boeckx N; Laboratory of Experimental Transplantation, University of Leuven, Leuven, Belgium., Slomp J; Department of Clinical Chemistry, Medisch Spectrum Twente/Medlon, Enschede, The Netherlands., Preijers F; Department of Laboratory Medicine-Laboratory for Hematology, Radboud UMC, Nijmegen, The Netherlands., Te Marvelde JG; Department of Immunology, Laboratory Medical Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Van NM; Laboratory of Clinical and Tumor Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Heijs A; Department of Clinical Chemistry, Medisch Spectrum Twente/Medlon, Enschede, The Netherlands., Huys E; Department of Laboratory Medicine-Laboratory for Hematology, Radboud UMC, Nijmegen, The Netherlands., van der Holt B; Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., de Greef GE; Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Kelder A; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands., Schuurhuis GJ; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.

Publikováno v: Leukemia research [Leuk Res] 2019 Jan; Vol. 76, pp. 39-47. Date of Electronic Publication: 2018 Nov 27.

Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial.

Autor: Stevens-Kroef MJ; Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands., Olde Weghuis D; Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands., ElIdrissi-Zaynoun N; Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands., van der Reijden B; Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands., Cremers EMP; Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., Alhan C; Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., Westers TM; Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., Visser-Wisselaar HA; Department of Hematology, Erasmus MC Cancer Institute, HOVON Data Center, Erasmus University Medical Center-Daniel den Hoed, Rotterdam, The Netherlands., Chitu DA; Department of Hematology, Erasmus MC Cancer Institute, HOVON Data Center, Erasmus University Medical Center-Daniel den Hoed, Rotterdam, The Netherlands., Cunha SM; Department of Hematology, Erasmus MC Cancer Institute, HOVON Data Center, Erasmus University Medical Center-Daniel den Hoed, Rotterdam, The Netherlands., Vellenga E; Department of Experimental Hematology, University Medical Center Groningen, Groningen, The Netherlands., Klein SK; Department of Internal Medicine, Meander Medisch Centrum, Amersfoort, The Netherlands., Wijermans P; Department of Internal Medicine, Haga Ziekenhuis, The Hague, The Netherlands., de Greef GE; Department of Hematology, Erasmus University Medical Center-Daniel den Hoed, Rotterdam, The Netherlands., Schaafsma MR; Department of Internal Medicine, Medisch Centrum Twente, Enschede, The Netherlands., Muus P; Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands., Ossenkoppele GJ; Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., van de Loosdrecht AA; Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., Jansen JH; Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.

Publikováno v: Genes, chromosomes & cancer [Genes Chromosomes Cancer] 2017 Jul; Vol. 56 (7), pp. 524-534. Date of Electronic Publication: 2017 Mar 31.

Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes.

Autor: Cremers EM; Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, The Netherlands., Westers TM; Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, The Netherlands., Alhan C; Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, The Netherlands., Cali C; Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, The Netherlands., Visser-Wisselaar HA; HOVON Data Center, Erasmus MC Cancer Institute, Clinical Trial Center, Rotterdam, The Netherlands., Chitu DA; HOVON Data Center, Erasmus MC Cancer Institute, Clinical Trial Center, Rotterdam, The Netherlands., van der Velden VH; Department of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands., Te Marvelde JG; Department of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands., Klein SK; Department of Internal Medicine, Meander Medical Center, Amersfoort, The Netherlands., Muus P; Department of Hematology, Radboud University Medical Centre, Nijmegen, The Netherlands., Vellenga E; Department of Hematology, University Medical Center Groningen, The Netherlands., de Greef GE; Department of Hematology Erasmus MC Cancer Institute Rotterdam, The Netherlands., Legdeur MC; Department of Internal Medicine, Medisch Spectrum Twente, Enschede, The Netherlands., Wijermans PW; Department of Internal Medicine, Haga Ziekenhuis, The Hague, The Netherlands., Stevens-Kroef MJ; Department of Human Genetics, Radboud University Medical Centre, Nijmegen, The Netherlands., Silva-Coelho PD; Laboratory of Hematology, Radboud University Medical Centre, Nijmegen, The Netherlands., Jansen JH; Laboratory of Hematology, Radboud University Medical Centre, Nijmegen, The Netherlands., Ossenkoppele GJ; Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, The Netherlands., van de Loosdrecht AA; Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, The Netherlands a.vandeloosdrecht@vumc.nl.

Publikováno v: Haematologica [Haematologica] 2017 Feb; Vol. 102 (2), pp. 320-326. Date of Electronic Publication: 2016 Sep 22.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.